McKesson(MCK) - 2026 Q3 - Earnings Call Transcript

Financial Data and Key Metrics Changes - Revenue increased by 11% to $106.2 billion, driven by broad-based growth across the business and higher prescription volumes [19][25] - Adjusted earnings per diluted share rose by 16% to $9.34, reflecting strong operational performance [21][25] - Operating profit increased by 13% year-over-year to $1.7 billion, supported by demand for access solutions and specialty distribution [20][25] Business Line Data and Key Metrics Changes - North American pharmaceutical revenues grew by 9% to $88.3 billion, with GLP-1 distribution revenues reaching $14 billion, up 26% year-over-year [21][22] - Oncology and multispecialty segment revenues surged by 37% to $13 billion, with operating profit increasing by 57% to $366 million [22][23] - Prescription technology solutions segment revenues rose by 9% to $1.5 billion, with operating profit up 18% to $277 million [23] Market Data and Key Metrics Changes - The U.S. Oncology Network now includes approximately 3,400 providers, with significant contributions from the integration of Florida Cancer Specialists and PRISM Vision [6][8] - The company reported strong demand for biopharma services, adding over 50 new programs across 43 unique brands during the quarter [9][60] Company Strategy and Development Direction - The company is focused on oncology and multispecialty services, leveraging its scale and leadership to meet evolving market needs [6][8] - Investments are being made in technology and automation to enhance operational efficiency and improve patient access to medications [10][36] - The company is progressing with the separation of its medical-surgical business, aiming for an IPO by the second half of calendar 2027 [15][16] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to sustain momentum and execute strategic priorities, raising full-year EPS guidance to $38.80-$39.20, reflecting 17%-19% growth [4][25] - The company anticipates revenue growth of 12%-16% and operating profit growth of 13%-17% for the full year, supported by strong third-quarter performance [25][26] Other Important Information - The company completed the divestiture of its Norwegian operations, marking the final step in its exit from Europe [18] - Free cash flow for the quarter was reported at $1.1 billion, with plans to repurchase approximately $2.5 billion of shares [24][32] Q&A Session Questions and Answers Question: Can you talk about the specific investments you're making in technology and automation? - Management highlighted investments in AI and automation to improve workflows, allowing employees to support more patients efficiently during the annual verification season [35][36] Question: How should we think about the longer-term opportunity to improve margins in that segment? - Management noted that operating margins have grown over 130 basis points year-over-year, with a focus on automating capabilities and services for biopharma partners [38] Question: What are the key drivers of growth in the North American pharmaceutical segment? - Management pointed to strong specialty distribution growth and operational efficiency gains as key drivers of growth in the segment [40][52]